Cereno Scientific to present preclinical data for candidate drug CS585 at EHA2023 Hybrid Congress – the premier medical congress for hematology
Cereno Scientific (XSAT: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that an abstract on preclinical drug candidate CS585 has been accepted as an oral presentation by the Scientific Program Committee at the European Hematology Association (EHA) 2023 Hybrid Congress in Frankfurt, Germany, on June 8-11. The abstract “Sustained inhibition of platelet activity and thrombosis via IV and oral administration of CS585” will be presented by Dr. Michael Holinstat, lead of Cereno’s preclinical development programs at University of